



600-1-276CIP

THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Albert et al.

SERIAL NO. : 09/804,584

EXAMINER : Karen A. Canella

FILED : March 12, 2001

ART UNIT : 1642

FOR : METHODS FOR ABROGATING A CELLULAR IMMUNE
RESPONSE

RECEIVED

DEC 11 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on December 4, 2002.

Anne M. Jones

Name of person depositing mail

Anne M. Jones 12/4/02.
Signature of person depositing mail

RESPONSE TO SPECIES ELECTION

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

The following reply is responsive to the Requirement for Species Election mailed November 6, 2002, due for a response on December 6, 2002.

The Examiner has required an election of species for one of the patentably distinct species of the claimed invention under 35 U.S.C. § 121:

I. (a) a method wherein absence of effective CD+4 T cell help is attained by exclusion of CD+4 T cells,

(b) a method wherein inhibition or elimination of effective CD+4 T cell help is attained by using a monoclonal antibody to a TNF superfamily member, or a monoclonal antibody to a TNF superfamily receptor,

(c) a method wherein inhibition or elimination of effective CD+4 T cell help is attained by inhibiting the formation of mature forms of MHC II peptide complexes within the dendritic cell, and

(d) a method wherein inhibition or elimination of effective CD+4 T cell help is attained by inhibiting signaling consequent to dendritic cell-T cell engagement.

II. The pre-selected antigens that are:

- (a) tumor antigens
- (b) viral antigens
- (c) self antigens, or
- (d) transplantation antigens.

Applicants hereby elect (d) from Group I: a method wherein inhibition or elimination of effective CD+4 T cell help is attained by inhibiting signaling consequent to dendritic cell-T cell engagement; and (b) from Group II: viral antigens.

Fees

No fees are believed to be necessitated by the instant response. However, should this be in error, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or to credit any overpayments.

Respectfully submitted,



Veronica Mallon, Ph.D.
Agent for Applicants
Registration No. P-52,491

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800